NPHLA Intelligence
Clinical Trial Watch
Trials NPHLA follows, synchronised from ClinicalTrials.gov. We flag what matters (new registrations, changes in status and newly posted results) and ignore routine record edits. Every therapy in a trial is investigational.
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim. Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Investigational — not approved for the use studied.
- A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
Kailera. Conditions: End Stage Renal Disease; Renal Impairment; Obesity; Overweight. Investigational — not approved for the use studied.
- Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
AstraZeneca. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S. Conditions: Obesity; Type 2 Diabetes. Investigational — not approved for the use studied.
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Regeneron Pharmaceuticals. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Investigational — not approved for the use studied.
- TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
Centre Hospitalier Universitaire Dijon. Conditions: Double Diabetes. Investigational — not approved for the use studied.
- GLYCOTIME: Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and Diabetes
German Institute of Human Nutrition. Conditions: Prediabetes; Type 2 Diabetes; Obesity &Amp; Overweight. Investigational — not approved for the use studied.
- A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
Viking Therapeutics, Inc.. Conditions: Obese Adults. Investigational — not approved for the use studied.
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals. Conditions: Overweight or Obesity. Investigational — not approved for the use studied.
- ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company. Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Investigational — not approved for the use studied.
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
National Institute on Alcohol Abuse and Alcoholism (NIAAA). Conditions: Healthy Volunteers; Overweight. Investigational — not approved for the use studied.
- Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Conditions: Obesity (Disorder); Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
M.D. Anderson Cancer Center. Conditions: Diabetes; Prostate Cancer. Investigational — not approved for the use studied.
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Arrowhead Pharmaceuticals. Conditions: Obesity. Investigational — not approved for the use studied.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
Ascletis Pharma (China) Co., Limited. Conditions: Chronic Weight Management. Investigational — not approved for the use studied.
- COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company. Conditions: Crohn's Disease; Obesity or Overweight. Investigational — not approved for the use studied.
- COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company. Conditions: Ulcerative Colitis; Obesity or Overweight. Investigational — not approved for the use studied.
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Eli Lilly and Company. Conditions: Obesity; Weight Gain. Investigational — not approved for the use studied.
- ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 1; Overweight; Obesity. Investigational — not approved for the use studied.
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Investigational — not approved for the use studied.
- RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Urinary Incontinence,Stress. Investigational — not approved for the use studied.
- ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Eli Lilly and Company. Conditions: Peripheral Arterial Disease. Investigational — not approved for the use studied.
- ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Meta…. Investigational — not approved for the use studied.
- ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Eli Lilly and Company. Conditions: Osteoarthritis. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Eli Lilly and Company. Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Investigational — not approved for the use studied.
- ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. Conditions: Obesity. Investigational — not approved for the use studied.
- IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Innovent Biologics (Suzhou) Co. Ltd.. Conditions: Overweight; Healthy Participants; Obesity. Investigational — not approved for the use studied.
- The Evira Study: Additional Support During Obesity Treatment
Karolinska Institutet. Conditions: Childhood Obesity; Treatment Adherence. Investigational — not approved for the use studied.
- RAMBO: The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Novo Nordisk A/S. Conditions: Obesity. Investigational — not approved for the use studied.
- REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- PROBIO-GLP1: Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
Hospices Civils de Lyon. Conditions: Obesity &Amp; Overweight; Digestive Disorders. Investigational — not approved for the use studied.
- ZQL007: Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
University of Virginia. Conditions: Type2 Diabetes. Investigational — not approved for the use studied.
- FLAMES: Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic. Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfun…. Investigational — not approved for the use studied.
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University. Conditions: Obesity & Overweight; Diabetes (DM). Investigational — not approved for the use studied.
- Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Novo Nordisk A/S. Conditions: Obesity. Investigational — not approved for the use studied.
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
University of Florida. Conditions: Endometrioid Endometrial Adenocarcinoma. Investigational — not approved for the use studied.
- ZQL008: Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
University of Virginia. Conditions: Metabolic Syndrome. Investigational — not approved for the use studied.
- GZBF: Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech. Conditions: Obesity. Investigational — not approved for the use studied.
- BICEP: Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Massachusetts General Hospital. Conditions: Obesity; Body Composition. Investigational — not approved for the use studied.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Trial listings are not recommendations to enrol or prescribe.